Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 16/20 | 0.60 |
| ▸ | AKT1 | P31749 | 15/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18203558 | 0.81 | AKT1 (0.56) | AKT2AKT1NPC1RAB9A | |
| SCHEMBL1429195 | 0.80 | AKT1 (0.63) | AKT2AKT1NPC1GAARAB9A | |
| SCHEMBL360844 | 0.75 | AKT2 (1.00) | AKT2AKT1 | |
| SCHEMBL360920 | 0.75 | AKT2 (1.00) | AKT2AKT1 | |
| SCHEMBL28851910 | 0.74 | GAA (0.52) | AKT2AKT1NPC1GAARAB9A | |
| SCHEMBL1691573 | 0.74 | SLC2A1 (0.52) | AKT2AKT1NPC1GAARAB9A | |
| SCHEMBL10021266 | 0.74 | NPC1 (0.66) | AKT2AKT1NPC1GAARAB9A | |
| SCHEMBL4564805 | 0.74 | NPC1 (0.66) | AKT2AKT1NPC1GAARAB9A | |
| SCHEMBL12503412 | 0.72 | AKT1 (0.68) | AKT2AKT1 | |
| SCHEMBL6526380 | 0.72 | MAPT (0.63) | AKT2AKT1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2062893-A1 | Fused imidazoles for cancer treatment | Bayer Schering Pharma AG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | AKT2 2/4885AKT1 3/4885NPC1 1448/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | AKT2 2/4885AKT1 3/4885NPC1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.